Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Cios A et al. | 2021 | intact cell/cell culture, HEK293 (kidney cells), 786-O, 769-P, and Caki1 (clear cell renal carcinoma cell lines) | magnetic field, 50/60 Hz | 4.5 mT |
Ding GR et al. | 2001 | intact cell/cell culture, MCF-7 (human breast cancer cell line) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
Tian F et al. | 2002 | intact cell/cell culture, CHO-K1 (Chinese hamster ovary K1) cells (Ku80-proficient) und xrs5 cells (Ku80-defizient; radiation sensitive mutant isolated from CHO-K1 cells) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
Ding GR et al. | 2004 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz | 5 mT |
Akbarnejad Z et al. | 2017 | intact cell/cell culture, U87 (human glioblastoma cell line) | magnetic field, signals/pulses, 50/60 Hz | 5–10 mT |
Yin C et al. | 2016 | intact cell/cell culture, primary hippocampal neurons from newborn Sprague-Dawley rats | magnetic field, 50/60 Hz, co-exposure | 8 mT |
Zhang H et al. | 2016 | animal, mouse/ICR | magnetic field, 50/60 Hz, co-exposure | 8 mT |
Berg H | 2003 | intact cell/cell culture, human myeloid leukemia cell line (K-562) and human non-Hodgkin lymphoma cell line (U-937) | magnetic field, 50/60 Hz, co-exposure | 8–55 mT |
Berg H et al. | 2003 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) and U937 cells (human leukemic monocyte cell line) and human lymphocytes | magnetic field, 50/60 Hz, co-exposure | 10–35 mT |
Baharara J et al. | 2016 | intact cell/cell culture, A2780 cells (cisplatin-resistant human ovarian adenocarcinoma cells) | magnetic field, 50/60 Hz, co-exposure | 20 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.